Stock Analysis
Arcus Biosciences, Inc. (RCUS) Stock Analysis
Arcus Biosciences, Inc. (RCUS) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Arcus Biosciences, Inc. (RCUS) currently has an AIQ Score of 39/100, indicating a bearish setup. Value is the strongest factor at 43/100. Momentum is the weakest current factor at 34/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
RCUS at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $17.43 |
| AIQ Score | 39/100 |
| Overall View | Bearish |
| Technical Analysis Consensus | Strong Sell |
| Market Cap | $2.22B |
| P/E Ratio (TTM) | -4.76 |
| Forward P/E | — |
| EPS (Q3 FY2026) | -$1.00 |
| Revenue (Q3 FY2026) | $9M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 1.56 |
| Volume | 1.14M |
| 52-week range | $17.03-$31.74 |
| RSI 14 | 35.06 |
| 50-Day SMA | $22.62 |
| 200-Day SMA | $24.47 |
| Analyst Price Target | $45.50 |
| Next Earnings | Feb 24, 2027 |
RCUSArcus Biosciences, Inc.
Healthcare / Biotechnology
Low Priority
Relative Laggard
Latest quote
- Momentum34
- Value43
- Quality41
- Risk resilience42
- Sentiment—
RCUS Stock Analysis Summary
Arcus Biosciences, Inc. (RCUS) currently has an AIQ Score of 39/100, indicating a bearish setup. Value is the strongest factor at 43/100. Momentum is the weakest current factor at 34/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bearish regime, RCUS has AIQ Score of 39/100 with Value base of 43/100 and fading Momentum at 34/100. Wait for component alignment before adding exposure.
Healthcare · -1.91% stock move · RCUS classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is RCUS Bullish or Bearish Right Now?
RCUS currently has a bearish overall setup. Value is the strongest factor at 43/100, while Momentum is weakest at 34/100. The current evidence suggests a bearish setup.
- - Analyst target implies +161.04% upside from the latest quote.
- - Value is the current constraint at 43/100.
- - Momentum is weak at 34/100.
- - Risk Resilience is weak at 42/100.
- - Price is -28.77% below its 200-day SMA.
- - Technical consensus has more sell votes than buy votes (34 vs 7).
Current Consensus
RCUS's Technical Analysis Consensus is currently Strong Sell, with 7 buy, 5 neutral, and 34 sell votes. RCUS's 14-day RSI is 35.06, which places the stock in a weaker momentum range. RCUS's beta is 1.56, indicating greater market sensitivity than the broad market.
What Changed in RCUS?
The largest recent change in RCUS is Value moving up by 3.0 points over the available 7-day comparison window. Value remains the strongest visible factor.
What Would Change the RCUS Outlook?
The current bearish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
RCUS Decision Framework
Public evidence layers, setup checks, and risk context for Arcus Biosciences, Inc..
Arcus Biosciences, Inc. (RCUS) Stock Analysis
Arcus Biosciences, Inc. has an AIQ Score of 39/100 in a Bearish regime. Value is strongest at 43/100. Beta is 1.56, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | RCUS is in a Bearish AIQ regime with score 39/100. |
| Signal Conflict | The primary conflict is that value leads at 43/100 while momentum lags at 34/100. |
| Factor Evidence | Momentum 34/100 · Value 43/100 · Quality 41/100 · Risk 42/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Value is the strongest factor at 43/100.
Momentum is 34/100 and RSI (14) is 35.1.
RCUS is in a Bearish regime at 39/100.
Risk factor is 42/100 with beta 1.56 and annual volatility 62.65%.
Current conflict: value leads at 43/100 while momentum lags at 34/100.
RCUS Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
RCUS Fundamentals
RCUS valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
RCUS Technical Analysis
RCUS technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
RCUS Stock Catalysts
Track RCUS earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
RCUS Dividend Analysis
RCUS dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
RCUS Financial Data
RCUS revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
RCUS Risk Analysis
RCUS volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
RCUS Stock News
RCUS stock news, market tone, recent headlines, and catalyst context.
RCUS vs Biotechnology Peers
Current peer cohort: RCUS · REPL · RLAY · RVMD · RYTM. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| RCUS Current stock | 39/100 | 43/100 | 34/100 | 42/100 | 0.05 | 62.65% | Current |
| REPL Replimune Group, Inc. | 60/100 | — | 97/100 | 26/100 | 1.3 | 187.93% | RCUS vs REPL |
| RLAY Relay Therapeutics, Inc. | 56/100 | 37/100 | 76/100 | 52/100 | 1.84 | 65.80% | RCUS vs RLAY |
| RVMD Revolution Medicines, Inc. | 55/100 | 39/100 | 73/100 | 59/100 | 1.69 | 68.69% | RCUS vs RVMD |
| RYTM Rhythm Pharmaceuticals, Inc. | 62/100 | 52/100 | 72/100 | 57/100 | 0.52 | 54.57% | RCUS vs RYTM |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for RCUS: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching RCUS
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for RCUS
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
RCUS Stock FAQ
What is RCUS stock price today?
Arcus Biosciences, Inc.'s current stock price is $17.43. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is RCUS bullish or bearish right now?
RCUS's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is RCUS's market cap?
RCUS's market cap is $2.22B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is RCUS's current P/E ratio?
RCUS's current P/E ratio is -4.76 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is RCUS's RSI?
RCUS's 14-day RSI is 35.06 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is RCUS above its 50-day and 200-day moving averages?
RCUS is -22.94% from its 50-day SMA and -28.77% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is RCUS's next earnings date?
RCUS's next earnings date is currently listed as Feb 24, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does RCUS pay a dividend?
RCUS's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.